Allarity Therapeutics, Inc. Class Action Lawsuit - ALLR

The filed complaint alleges that Allarity Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: On July 22, 2024, Allarity filed a current report on Form 8-K with the SEC. The filing reveals that the Company received a "Wells Notice" from the SEC. The Company stated in its filing that, "the Wells Notice relates to the Company's disclosures regarding meetings with the United States Food and Drug Administration (the 'FDA') regarding the Company's NDA [New Drug Application] for Dovitinib or Dovitinib-DRP," and that "Allarity also understands that three of its former officers received Wells Notices from the SEC relating to the same conduct." Additionally, "the Wells Notice informed the Company that the SEC Staff has made a preliminary determination to recommend that the SEC file an enforcement action against the Company that would allege certain violations of the federal securities laws." The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

In order to be eligible to join the ALLR class action lawsuit, you must have incurred a loss on shares of Allarity Therapeutics, Inc. purchased during the class period listed above.